As economic growth hinges on the ability of companies to innovate freely, recent actions by the FTC and DOJ are raising serious concerns. In this Forbes article, Market Institute Senior Fellow John Tamny examines the dangers of these agencies’ frequent monopoly accusations and leaks, which destabilize corporations and drain essential Read more…
In a recent turn of events, Senator Bernie Sanders has raised eyebrows by calling for the subpoena of two drug company CEOs, sparking both curiosity and concern. Market Institute President Charles Sauer’s new article in Townhall delves into Sanders’ unconventional tactics, questioning the wisdom of his confrontational approach to the Read more…
President Biden’s populist approach to healthcare reform, focusing on price controls, has stirred controversy in the pharmaceutical industry. A new article by Market Institute President Charles Sauer in The Hill highlights the potential consequences of this strategy, including drug shortages and stifled innovation. By exploring the lessons learned from Japan’s Read more…
In the world of intellectual property, inventors and innovators have long relied on the protection of patents to safeguard their creations. However, in recent years, the Patent Trial and Appeal Board (PTAB) has become a contentious battleground where patents are challenged and, in some cases, invalidated. Market Institute President Charles Read more…
The National Institutes of Health has asked the public to submit written comments responding to a Workshop on Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer. See comment below: More innovation is fairly easy – create the right incentives For good or bad – people, businesses, investors, Read more…
The Market Institute President Charles Sauer has a new article in Real Clear Markets on a bill recently introduced in Congress called the PREVAIL Act. If passed, it will help level the playing field for inventors, most notably by attempting to fix the Patent Trial and Appeals Board. He writes: Read more…
The Market Institute President Charles Sauer has a new article in Real Clear Policy looking at the problems with price setting drug prices. There are attempts by the Biden Administration to use “March In” rights to implement price controls – even at the expense of future innovation. He writes: “In Read more…
The Market Institute President Charles Sauer has a new article in the Washington Examiner’s Restoring America series looking at why Senator Patrick Leahy (D-VT) is ending his tenure in the Senate with a patent bill that will harm inventors. “The 47-year-serving Democratic senator from Vermont, Patrick Leahy, is finishing his Read more…
Market Institute President Charles Sauer has a new article up at the Washington Examiner on how the United States Patent and Trademark Office has empowered innovation the last 4 years. President Trump’s legacy will be something that is debated for years to come, but his administration did have some redeeming Read more…